High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70036 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Marcin A Sowa and 8 co-authors. Institution: Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences, University of Reading, Reading, UK. Major MEDLINE topics: Lectins, C-Type, Podoplanin, Platelet Activation. 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Spanish Ministry of Science, Innovation and Universities, H2020 Marie Skłodowska-Curie Actions, Deutsche Forschungsgemeinschaft.
Abstract (original language)
Background and Purpose The C‐type lectin‐like receptor‐2 (CLEC‐2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis. Activation of CLEC‐2 leads to the phosphorylation of its cytoplasmic hemITAM domain and initiates a signalling cascade involving the kinase Syk. The aim of this study was to identify and characterise a novel small molecule inhibitor of CLEC‐2. Experimental Approach An AlphaScreen‐based high‐throughput screening was used to identify a small molecule inhibitor of the CLEC‐2–podoplanin interaction. Binding site interactions were assessed using in silico modelling. Functional assays, including light transmission aggregometry, platelet spreading and phosphorylation assays, were used to evaluate the effect of a small molecule on CLEC‐2‐mediated platelet activation. Key Results A total of 18,476 small molecules were screened resulting in 14 candidates. Following secondary screening, one novel small molecule, MAS9, was taken forward for further characterisation. The binding sites of MAS9 to CLEC‐2 were predicted to share binding sites with the CLEC‐2 ligands podoplanin and rhodocytin. MAS9 inhibited CLEC‐2‐mediated platelet aggregation, spreading and signalling. MAS9 also resulted in inhibited fibrinogen binding. Conclusion and Implications MAS9 inhibits CLEC‐2‐mediated aggregation, platelet spreading and signalling, showing selectivity of CLEC‐2 inhibition over GPVI. This study paves the way for future preclinical assays to test the potential of MAS9 as a novel therapeutic tool to treat pathologies such as thromboinflammation and cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences, University of Reading, Reading, UK.
- Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
- Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
- Pivot Park Screening Centre, Oss, The Netherlands.
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
- Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany.
ORCID profiles: Marcin A Sowa, Yan Wu, Johannes A Eble, Jonathan M Gibbins, Ángel García, Alice Y Pollitt
Funding
- Spanish Ministry of Science, Innovation and Universities
- H2020 Marie Skłodowska-Curie Actions
- Deutsche Forschungsgemeinschaft
- National Centre for the Replacement Refinement and Reduction of Animals in Research
- Academy of Medical Sciences
Cite
APA
Sowa, M. A., Wu, Y., van Groningen, J., Di, Y., van den Hurk, H., Eble, J. A., Gibbins, J. M., García, Á., & Pollitt, A. Y. (2025). High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction. British Journal of Pharmacology. https://doi.org/10.1111/bph.70036
Vancouver
Sowa MA, Wu Y, van Groningen J, Di Y, van den Hurk H, Eble JA, et al. High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction. British Journal of Pharmacology. 2025. doi:10.1111/bph.70036
BibTeX
@article{Sowa2025,
author = {Sowa, Marcin A and Wu, Yan and van Groningen, Jan and Di, Ying and van den Hurk, Helma and Eble, Johannes A and Gibbins, Jonathan M and García, Ángel and Pollitt, Alice Y},
title = {High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70036}
}
EUVIMED